{"id":2396,"date":"2023-04-04T14:31:29","date_gmt":"2023-04-04T14:31:29","guid":{"rendered":"https:\/\/blog.trive.com\/?p=2396"},"modified":"2023-04-04T14:31:30","modified_gmt":"2023-04-04T14:31:30","slug":"reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come","status":"publish","type":"post","link":"https:\/\/blog.trive.com\/es\/inversion\/reata-pharmaceuticals-incs-share-price-surges-146-44-hay-mas-crecimiento-por-venir\/","title":{"rendered":"El precio de las acciones de Reata Pharmaceuticals Inc aumenta 146.44%. \u00bfHay m\u00e1s crecimiento por venir?"},"content":{"rendered":"<p>Reata Pharmaceuticals Inc (NASDAQ: RETA) ha invertido mucho en su ejercicio de investigaci\u00f3n y desarrollo. En los \u00faltimos cinco a\u00f1os, los costos de investigaci\u00f3n y desarrollo aumentaron 11% sobre una base de tasa de crecimiento anual compuesta a $169.84M, lo que representa 60% de los gastos. A pesar de los costes significativos que pesan en el resultado final, el precio de las acciones de RETA ha subido 146.44% en lo que va del a\u00f1o gracias al optimismo que rodea a los \u00faltimos productos farmac\u00e9uticos aprobados de RETA que son \u00fanicos.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" loading=\"lazy\" width=\"831\" height=\"435\" src=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1.png\" alt=\"\" class=\"wp-image-2397\" srcset=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1.png 831w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1-300x157.png 300w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1-768x402.png 768w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1-18x9.png 18w\" sizes=\"(max-width: 831px) 100vw, 831px\" \/><\/figure>\n\n\n\n<p>El precio de las acciones de Reata normalmente ha superado al NASDAQ100 en los \u00faltimos cinco a\u00f1os, excepto el a\u00f1o pasado, cuando los costes de endeudamiento m\u00e1s altos redujeron fuertemente las valoraciones de las acciones. El precio de las acciones de RETA reaccion\u00f3 negativamente al entorno de tasas de inter\u00e9s m\u00e1s altas luego de un aumento en la deuda total de 2154% de 2021 a 2022, lo que llev\u00f3 a que los gastos por intereses aumentaran en 13% en el mismo per\u00edodo.\u00a0\u00a0\u00a0<\/p>\n\n\n\n<h2>T\u00e9cnicos<\/h2>\n\n\n\n<p>El precio de las acciones de RETA ha tenido una fuerte tendencia a la baja caracterizada por la formaci\u00f3n de un patr\u00f3n de canal descendente. El soporte y la resistencia se establecieron en los niveles de $19.17 y $115.17 por acci\u00f3n, respectivamente. La tendencia bajista se detuvo cuando los vol\u00famenes disminuyeron y el precio de las acciones se consolid\u00f3 lateralmente dentro de un patr\u00f3n rectangular. El precio rebot\u00f3 entre $19.17 y $41.58 por rango de acci\u00f3n durante un a\u00f1o.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Una ruptura por encima del nivel de $41.58 por acci\u00f3n en grandes vol\u00famenes podr\u00eda significar que los inversores alcistas est\u00e1n ansiosos por subir las acciones, ya que la batalla entre ellos y los bajistas termin\u00f3 con los alcistas del lado ganador. Si el impulso alcista persiste, es probable que los alcistas busquen el siguiente nivel de importancia en el nivel de $115.17 por acci\u00f3n, dejando espacio para una ganancia de 22.71% en el precio de la acci\u00f3n.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Alternativamente, si los inversores bajistas deshacen el trabajo de los alcistas, es probable que lleven el precio de las acciones a un retroceso. Los alcistas probablemente encontrar\u00e1n el nivel de la proporci\u00f3n \u00e1urea del retroceso de Fibonacci de 61.80% en $41.48 como un descuento tentador para comprar la acci\u00f3n si no participan en el movimiento, lo que llev\u00f3 al final del patr\u00f3n de consolidaci\u00f3n. Sin embargo, si la proporci\u00f3n \u00e1urea no se mantiene como soporte, el precio podr\u00eda retroceder 100%, dejando $19.17 como el siguiente nivel probable de inter\u00e9s para que los inversores alcistas se acumulen.\u00a0\u00a0<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" loading=\"lazy\" width=\"837\" height=\"427\" src=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta2.png\" alt=\"\" class=\"wp-image-2398\" srcset=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta2.png 837w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta2-300x153.png 300w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta2-768x392.png 768w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta2-18x9.png 18w\" sizes=\"(max-width: 837px) 100vw, 837px\" \/><\/figure>\n\n\n\n<h2><strong>Fundamentales<\/strong>\u00a0<\/h2>\n\n\n\n<p>Desde una perspectiva financiera, RETA ha tenido un desempe\u00f1o negativo, con una disminuci\u00f3n de los ingresos anuales de 80.71% a $2.22M. A pesar de recibir un fuerte golpe en la l\u00ednea superior, la utilidad bruta se mantuvo en territorio positivo, alcanzando $1.09M. Sin embargo, el resultado final qued\u00f3 fr\u00e1gil con una p\u00e9rdida de $311.90M, 4.88% m\u00e1s que el a\u00f1o anterior.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Sin embargo, con las finanzas apuntando al sur, el precio de las acciones de RETA no ha estado en una pendiente resbaladiza; en cambio, se mantuvo estable a positivo gracias al progreso en el desarrollo de productos de RETA. El precio de las acciones subi\u00f3 146.44% debido a la aprobaci\u00f3n regulatoria de Skyclarys, un f\u00e1rmaco que trata un trastorno neurol\u00f3gico raro. Los analistas esperan que fluyan vientos favorables hacia los ingresos de RETA, y se pronostica que $1.2B ser\u00e1 el pico de ventas de Skyclarys dentro de la industria. La valoraci\u00f3n del negocio de productos farmac\u00e9uticos probablemente apuntar\u00e1 hacia el norte una vez que obtenga ingresos de nuevos productos.&nbsp;<\/p>\n\n\n\n<p>Despu\u00e9s de descontar los flujos de efectivo futuros, se obtuvo un valor razonable de $102.68, que podr\u00eda ser probable si RETA logra con \u00e9xito un crecimiento en las ventas de sus \u00faltimos productos. Con el precio actual de las acciones infravalorado, esto podr\u00eda dejar espacio para una ganancia al alza de 10.47% hacia el valor razonable.\u00a0\u00a0<\/p>\n\n\n\n<h2>Resumen<\/h2>\n\n\n\n<p>Fundamentalmente, el desempe\u00f1o de RETA es un tanto repelente, especialmente para los inversores impulsados por ganancias y pagos de dividendos. Sin embargo, con el compromiso de la organizaci\u00f3n de invertir en Investigaci\u00f3n y Desarrollo, se podr\u00edan desarrollar, introducir y agregar nuevas l\u00edneas de productos a la matriz de ingresos. Los inversores alcistas probablemente estar\u00e1n en una mejor posici\u00f3n comprando en los niveles de $41.48 o $19.17 por acci\u00f3n.&nbsp;&nbsp;&nbsp;<\/p>\n\n\n\n<p><em>Fuentes: Reata Pharmaceuticals Inc, TradingView, Koyfin\u00a0<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise. Over the past five years, Research and development costs have surged 11% on a compounded annual growth rate basis to $169.84M, making up 60% of the expenses. Despite significant costs weighing on the bottom line, RETA\u2019s share price has surged 146.44% [&hellip;]<\/p>","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?<\/title>\n<meta name=\"description\" content=\"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.trive.com\/es\/inversion\/reata-pharmaceuticals-incs-share-price-surges-146-44-hay-mas-crecimiento-por-venir\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?\" \/>\n<meta property=\"og:description\" content=\"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.trive.com\/es\/inversion\/reata-pharmaceuticals-incs-share-price-surges-146-44-hay-mas-crecimiento-por-venir\/\" \/>\n<meta property=\"og:site_name\" content=\"Trive Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T14:31:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-04T14:31:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"831\" \/>\n\t<meta property=\"og:image:height\" content=\"435\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?\" \/>\n<meta name=\"twitter:description\" content=\"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1.png\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?\",\"datePublished\":\"2023-04-04T14:31:29+00:00\",\"dateModified\":\"2023-04-04T14:31:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/\"},\"wordCount\":597,\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"articleSection\":[\"Investment\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/\",\"url\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/\",\"name\":\"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/#website\"},\"datePublished\":\"2023-04-04T14:31:29+00:00\",\"dateModified\":\"2023-04-04T14:31:30+00:00\",\"description\":\"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.\",\"breadcrumb\":{\"@id\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/blog.trive.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.trive.com\/#website\",\"url\":\"https:\/\/blog.trive.com\/\",\"name\":\"Trive Blog\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.trive.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/blog.trive.com\/#organization\",\"name\":\"Trive Blog\",\"url\":\"https:\/\/blog.trive.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"contentUrl\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"width\":723,\"height\":199,\"caption\":\"Trive Blog\"},\"image\":{\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\/\/blog.trive.com\/es\/author\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?","description":"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.trive.com\/es\/inversion\/reata-pharmaceuticals-incs-share-price-surges-146-44-hay-mas-crecimiento-por-venir\/","og_locale":"es_ES","og_type":"article","og_title":"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?","og_description":"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.","og_url":"https:\/\/blog.trive.com\/es\/inversion\/reata-pharmaceuticals-incs-share-price-surges-146-44-hay-mas-crecimiento-por-venir\/","og_site_name":"Trive Blog","article_published_time":"2023-04-04T14:31:29+00:00","article_modified_time":"2023-04-04T14:31:30+00:00","og_image":[{"width":831,"height":435,"url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_title":"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?","twitter_description":"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.","twitter_image":"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1.png","twitter_misc":{"Escrito por":"","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/#article","isPartOf":{"@id":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/"},"author":{"name":"","@id":""},"headline":"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?","datePublished":"2023-04-04T14:31:29+00:00","dateModified":"2023-04-04T14:31:30+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/"},"wordCount":597,"publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"articleSection":["Investment"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/","url":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/","name":"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?","isPartOf":{"@id":"https:\/\/blog.trive.com\/#website"},"datePublished":"2023-04-04T14:31:29+00:00","dateModified":"2023-04-04T14:31:30+00:00","description":"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.","breadcrumb":{"@id":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blog.trive.com\/"},{"@type":"ListItem","position":2,"name":"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?"}]},{"@type":"WebSite","@id":"https:\/\/blog.trive.com\/#website","url":"https:\/\/blog.trive.com\/","name":"Trive Blog","description":"","publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.trive.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/blog.trive.com\/#organization","name":"Trive Blog","url":"https:\/\/blog.trive.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/","url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","contentUrl":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","width":723,"height":199,"caption":"Trive Blog"},"image":{"@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blog.trive.com\/es\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts\/2396"}],"collection":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/comments?post=2396"}],"version-history":[{"count":1,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts\/2396\/revisions"}],"predecessor-version":[{"id":2399,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts\/2396\/revisions\/2399"}],"wp:attachment":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/media?parent=2396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/categories?post=2396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/tags?post=2396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}